MetaVia completes dose titration in Phase 1 obesity trial of DA-1726

MetaVia Inc. said on July 9, 2026 that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for obesity have completed dose titration and are now on their highest target doses in both study cohorts¹. The drug, DA-1726, is a novel oxyntomodulin analog that targets both the GLP-1 and glucagon receptors¹.

The Part 3 portion of the Phase 1 program is built around two 16-week titration cohorts testing one-step and two-step dose-escalation approaches meant to safely reach higher doses while optimizing tolerability¹. According to the release, patients in Part 3A titrated from 16 mg up to 48 mg, while those in Part 3B titrated from 16 mg to 32 mg and then to 64 mg¹.

CEO Hyung Heon Kim said reaching the highest planned dose levels in all active patients reinforces what the company called a favorable tolerability profile, adding that the company believes its titration strategy could offer a competitive edge over currently marketed obesity treatments¹. He also referenced earlier data, noting results from the prior Phase 1 multiple ascending dose study, including weight loss of 9.1% at the 48 mg dose after 8 weeks of treatment, along with waist circumference reductions, glycemic improvements, and early indications of liver benefit¹.

The trial's design calls for roughly 40 obese but otherwise healthy adult participants split into two parts of about 20 each, randomized 4:1 between active drug and placebo¹. The study is tracking safety, tolerability, pharmacokinetics and pharmacodynamics, with adverse events as primary endpoints¹. The company said it still expects to report Part 3 topline data in the fourth quarter of 2026¹.